Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Use of the glutamate NMDA receptor antagonist PK-Merz in acute stroke.

Literature DB >> 20464511

Use of the glutamate NMDA receptor antagonist PK-Merz in acute stroke.

O V Krivonos¹, N A Amosova, I G Smolentseva.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2010 PMID： 20464511 DOI： 10.1007/s11055-010-9292-6

Source DB: PubMed Journal: Neurosci Behav Physiol ISSN： 0097-0549

× No keyword cloud information.

15 in total

Review 1. [Plasticity of the nervous system].

Authors: W I Gusev; P R Kamchatnov
Journal: Zh Nevrol Psikhiatr Im S S Korsakova Date: 2004

2. Tolerability of the low-affinity, use-dependent NMDA antagonist AR-R15896AR in stroke patients: a dose-ranging study.

Authors: K R Lees; A G Dyker; A Sharma; G A Ford; M E Ardron; D G Grosset
Journal: Stroke Date: 2001-02 Impact factor: 7.914

3. Predicting treatment costs after acute ischemic stroke on the basis of patient characteristics at presentation and early dysfunction.

Authors: J J Caro; K F Huybrechts; H E Kelley
Journal: Stroke Date: 2001-01 Impact factor: 7.914

Review 4. Duration of neuroprotective treatment for ischemic stroke.

Authors: A G Dyker; K R Lees
Journal: Stroke Date: 1998-02 Impact factor: 7.914

5. Characteristics of academic medical centers and ischemic stroke outcomes.

Authors: L A Gillum; S C Johnston
Journal: Stroke Date: 2001-09 Impact factor: 7.914

6. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists.

Authors: Harold P Adams; Gregory del Zoppo; Mark J Alberts; Deepak L Bhatt; Lawrence Brass; Anthony Furlan; Robert L Grubb; Randall T Higashida; Edward C Jauch; Chelsea Kidwell; Patrick D Lyden; Lewis B Morgenstern; Adnan I Qureshi; Robert H Rosenwasser; Phillip A Scott; Eelco F M Wijdicks
Journal: Stroke Date: 2007-04-12 Impact factor: 7.914

7. [Antioxidant therapy in ischemic stroke].

Authors: Z A Suslina; T N Federova; M Iu Maksimova; T V Riasina; S L Stvolinskiĭ; E V Khrapova; A A Boldyrev
Journal: Zh Nevrol Psikhiatr Im S S Korsakova Date: 2000

8. Heterogeneity of stroke pathophysiology and neuroprotective clinical trial design.

Authors: Keith W Muir
Journal: Stroke Date: 2002-06 Impact factor: 7.914

9. NXY-059 for acute ischemic stroke.

Authors: Kennedy R Lees; Justin A Zivin; Tim Ashwood; Antonio Davalos; Stephen M Davis; Hans-Christoph Diener; James Grotta; Patrick Lyden; Ashfaq Shuaib; Hans-Göran Hårdemark; Warren W Wasiewski
Journal: N Engl J Med Date: 2006-02-09 Impact factor: 91.245

Use of the glutamate NMDA receptor antagonist PK-Merz in acute stroke.

Review 1. [Plasticity of the nervous system].

2. Tolerability of the low-affinity, use-dependent NMDA antagonist AR-R15896AR in stroke patients: a dose-ranging study.

3. Predicting treatment costs after acute ischemic stroke on the basis of patient characteristics at presentation and early dysfunction.

Review 4. Duration of neuroprotective treatment for ischemic stroke.

5. Characteristics of academic medical centers and ischemic stroke outcomes.

7. [Antioxidant therapy in ischemic stroke].

8. Heterogeneity of stroke pathophysiology and neuroprotective clinical trial design.

9. NXY-059 for acute ischemic stroke.

10. Combination therapy in ischemic stroke: synergistic neuroprotective effects of memantine and clenbuterol.

Review 1. The Function of the Mitochondrial Calcium Uniporter in Neurodegenerative Disorders.

2. Can Amantadine Ameliorate Neurocognitive Functions After Subarachnoid Haemorrhage? A Preliminary Study.

Review 3. Pharmacological interventions for unilateral spatial neglect after stroke.

Review 4. Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentials.